US panel endorses widespread use of Pfizer Covid-19 vaccine

Shots could begin within days, depending on how quickly the Food and Drug Administration signs off, as expected, on the expert committee’s recommendation.
In a 17-4 vote with one abstention, the government advisers concluded that the vaccine from Pfizer and its German partner BioNTech appears safe and effective for emergency use in adults and teenagers 16 and ov(AFP)
In a 17-4 vote with one abstention, the government advisers concluded that the vaccine from Pfizer and its German partner BioNTech appears safe and effective for emergency use in adults and teenagers 16 and ov(AFP)
Updated on Dec 11, 2020 05:32 AM IST
Copy Link
Washington | ByAssociated Press| Posted by Susmita Pakrasi

A U.S. government advisory panel endorsed widespread use of Pfizer’s coronavirus vaccine Thursday, putting the country just one step away from launching an epic vaccination campaign against the outbreak that has killed close to 300,000 Americans.

Shots could begin within days, depending on how quickly the Food and Drug Administration signs off, as expected, on the expert committee’s recommendation.

“This is a light at the end of the long tunnel of this pandemic,” said Dr. Sally Goza, president of the American Academy of Pediatrics.

In a 17-4 vote with one abstention, the government advisers concluded that the vaccine from Pfizer and its German partner BioNTech appears safe and effective for emergency use in adults and teenagers 16 and over.

That endorsement came despite questions about allergic reactions in two people who received the vaccine earlier this week when Britain became the first country to begin dispensing the Pfizer-BioNTech shot.

While there are a number of remaining unknowns about the vaccine, in an emergency, “the question is whether you know enough” to press ahead, said panel member Dr. Paul Offit of Children’s Hospital of Philadelphia. He concluded that the potential benefits outweigh the risks.

The decision came as Covid-19 cases surge to ever-higher levels across the U.S., with deaths setting an all-time, one-day record of more than 3,100 on Wednesday.

Pfizer has said it will have about 25 million doses of the two-shot vaccine for the U.S. by the end of December. But the initial supplies will be reserved primarily for health care workers and nursing home residents, with other vulnerable groups next in line until ramped-up production enables shots to become widely available on demand — something that will probably not happen until the spring.

Next week, the FDA will review a second vaccine, from Moderna and the National Institutes of Health, that appears about as protective as Pfizer-BioNTech’s shot. A third candidate, from Johnson & Johnson, which would require just one dose, is working its way through the pipeline. Behind that is a candidate from AstraZeneca and Oxford University.

U.S. health experts are hoping a combination of vaccines will ultimately enable the U.S. to conquer the outbreak.

But experts estimate at least 70% of the U.S. population will have to be vaccinated to achieve herd immunity, the point at which the virus can be held in check. That means it could be several months before things start get back to normal and Americans can put away their masks.

All eyes now turn to the FDA staff scientists who will make the final decision of whether to press ahead with large-scale immunizations with the Pfizer-BioNTech vaccine. FDA’s vaccine director Dr. Peter Marks said ahead of the expert meeting that a decision would come within “days to a week.”

The independent review by non-government experts in vaccine development, infectious diseases and medical statistics was considered critical to boosting Americans’ confidence in the safety of the shot, which was developed at breakneck speed less than a year after the virus was identified.

Regulators not only in Britain but in Canada have already approved the vaccine for use in their countries, and President Donald Trump and White House officials have complained for weeks about the pace of FDA’s careful review.

“Americans want us to do a scientific review, but I think they also want us to make sure we’re not wasting time on paperwork as opposed to going forward with the decision,” FDA Commissioner Stephen Hahn said before the meeting.

A positive vote for the vaccine was virtually assured after FDA scientists issued a glowing review of the vaccine earlier in the week. Agency staffers said data from Pfizer’s ongoing study of 44,000 people showed strong protection across different age groups, races and health conditions with no major, unexpected safety problems.

The Pfizer-BioNTech shot remains experimental because that final-stage study isn’t complete. As a result, the expert panel wrestled with a list of questions that have yet to be answered.

For example, while the vaccine is more than 90% effective in blocking the symptoms of Covid-19, the FDA’s advisers stressed it is not yet clear whether it can stop the silent, symptomless spread that accounts for up to half of all cases.

“Even though the individual efficacy of this vaccine is very, very, very high, you really as of right now do not have any evidence” that it will lower transmission, said Dr. Patrick Moore of the University of Pittsburgh. He urged Pfizer to take additional steps to answer that question.

Several of the dissenting panel members objected to authorizing the shot for 16- and 17-year-olds, given their small numbers in the study and the low risk they face from Covid-19.

Members worried, too, that Pfizer will lose its opportunity to answer critical questions once it begins offering the real vaccine to study participants who had been getting dummy shots up to now.

The company proposed gradually moving those patients to the vaccine group, with priority based on age, health conditions and other factors. Under that plan, 70-year-old participants would cross over before healthy 30-year-olds.

Pfizer must still show whether the vaccine works in children younger than 16 and in pregnant women.

On the safety front, as widespread vaccinations begin, the first recipients will be closely tracked by government health authorities since studies in tens of thousands of people can’t detect rare risks that strike 1 in a million. Hanging over the meeting were the British allergic reactions and a warning from authorities there that people with a history of serious reactions shouldn’t get the vaccine for now.

Pfizer representatives said they have seen no signs of allergic reactions in their trial. But some of the FDA advisers fear the British warning will deter millions of Americans with allergies who might benefit from the Covid-19 vaccine from giving it a try, and urged additional studies to try to settle the issue.

“This issue is not going to die until we have better data,” Offit said.

SHARE THIS ARTICLE ON
Close Story
QUICKREADS

Less time to read?

Try Quickreads

  • Another bomb exploded inside a mosque in the capital Kabul late on Wednesday, killing at least two people and wounding 10 others.

    At least 9 killed as 3 bombs strike minibuses in Afghan city: police

    Three bombs tore through minibuses in Afghanistan's northern city of Mazar-i-Sharif on Wednesday, killing at least nine people, police said. "The bombs were placed on three minibuses in different districts of the city," Balkh provincial police spokesman Asif Waziri told AFP, adding that 15 other people were wounded. Another bomb exploded inside a mosque in the capital Kabul late on Wednesday, killing at least two people and wounding 10 others, the interior ministry said.

  • A bomb exploded inside a mosque in the capital Kabul late on Wednesday.

    Afghanistan: 16 killed as four blasts tear through minibuses, Kabul mosque 

    At least 16 people were killed after a blast tore through a mosque in Afghanistan's capital Kabul and three blasts ripped through three minibuses northern city of Mazar-i-Sharif on Wednesday. A spokesman for Kabul's commander said at least two people were injured in the blast on a mosque in Kabul. Emergency hospital said in a tweet it had received five bodies from the blast and more than a dozen wounded patients, reported Reuters.

  • PTI workers set on fire a tree in Islamabad's Blue Area.

    Pakistan on boil: Trees torched, tear gas fired during Imran Khan's march

    Clashes erupted across several cities of Pakistan amid the Azadi March call by the ousted prime minister Imran Khan Niazi. After Karachi, Lahore and parts of Khyber Pakhunkhwa, the Pakistan Tehreek-i-Insaf supporters and workers resorted to violence in the federal capital Islamabad, where the party chief is set to hold the rally.

  • Pakistan's former all-rounder Mohammad Hafeez.

    ‘No petrol in any station, no cash in ATMs’: Pakistan's Mohammad Hafeez 

    On a day Lahore witnessed clashes between supporters of Imran Khan's Pakistan Tehreek-i-Insaf and police, former Pakistan cricketer Mohammad Hafeez took to Twitter and slammed the Pakistani establishment over the shortage of fuel and cash, tagging prominent politicians in the country. Political and economic volatility has deepened in the nuclear-armed nation ahead of a likely announcement by the International Monetary Fund later in the day on whether it will resume a $6 billion rescue package.

  • FILE - In this photo taken on April 22, 2013, new recruits practice charging with bayonets at a military training center in Hsinchu County, northern Taiwan. (AP)

    China conducts military exercise around Taiwan to warn U.S.

    China's People's Liberation Army on Wednesday said it has conducted a military exercise around Taiwan as a warning against its “collusive activities” with the United States, two days after President Joe Biden said Washington would get involved militarily if China were to try to take the self-ruled island by force. “This is a stern warning to the recent collusive activities by the US and Taiwan secessionists,” Senior a spokesperson of the Eastern Theatre Command, Colonel Shi Yi was quoted in Chinese state media as saying.

SHARE
Story Saved
×
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Thursday, May 26, 2022